Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2021

View Archived Issues

Surface Ophthalmics initiates phase II trial of SURF-200 for acute dry eye

In vivo data on IHL-675A supports expansion of indications to include COPD and asthma

Thrombin trivalent inhibitors inspired by native peptidic inhibitors from hematophagous arthropods

CD22 is a potential target for CAR T-cell therapy in LBCL after failure of autologous CAR19 therapy

FDA places clinical hold on phase IIa study of SPR-720

Ono Pharmaceutical divulges KDM5A inhibitors

Kymera Therapeutics patents CRBN inhibitors

Pfizer presents new TLR agonists

Scenic Immunology synthesizes new QC and/or QPCTL inhibitors

Good T Cells patents molecules for treating immune checkpoint inhibitor-resistant cancer

Phase III KESTREL study of Imfinzi in HNSCC does not meet its primary or secondary endpoints

SerpinPC found useful in patients with severe hemophilia

FDA approves phase I/IIa study of HDP-101 in multiple myeloma

Single-cell resolution reveals cell type, targets, for neuroblastoma

Updated patient eligibility and first-in-human data for BAY-2599023

Korean MFDS grants conditional marketing authorization for Regkirona for COVID-19

Bevacizumab shows potential benefit in COVID-19 patients

FDA grants accelerated approvals of Ukoniq for marginal zone lymphoma and follicular lymphoma

Phase I/II results for TAK-754 gene therapy in severe hemophilia A

Alphamab initiates phase I/II study of KN-046 with donafenib in HCC

Safety, immune responses reported for SARS-CoV-2 vaccine BBV-152 in clinical trial

PCOS passed on in the epigenes

Preclinical data presented for GD2-B7H3 CART in metastatic neuroblastoma

FDA approves Breyanzi for relapsed or refractory large B-cell lymphoma

Phase I trial of IDE-397 for solid tumors with MTAP deletion cleared to begin in U.S.

FDA clears IND for phase I/II study of PBKR-03 for Krabbe disease

Sinovac reports phase III data on CoronaVac